237 research outputs found
New Mobilization Strategies for Collection of Peripheral Blood Progenitor Cells for Lymphoma and Myeloma Patients
Control Natural Language Query Editor Guided by OWL/XML Path
It is become difficult when common user try to access semantic web application or any one ontology database-like gene ontology, plant ontology etc. Because either he/she don’t know about ontology technology or about no of concepts present in the ontology database. So only expert user can handle the applications or database. To avoid this problem, I have developed the Controlled natural language query editor guided by xml path. Here ontology data is get used in the xml file format and then that file is get used to generate ontology tree. Ontology tree is work as suggester for user in the generation of their query. Query then fire on xml/ontology file to retrieve desire result
419: Establishment of a long-term allogeneic blood and marrow program for early detection of complication and measuring outcomes
Establishment of a long-term allogeneic blood and marrow follow-up program for early detection of complications and measuring outcomes
Predictive Effects of Malnutrition Indicators for Morbidity and Mortality Among Blood and Marrow Transplantation Recipients: A Retrospective Chart Review
Allogeneic hsct with reduced intensity conditioning regimens in high risk patients with myelofibrosis
n/
Comparison of Busulfan + Melphalan to Melphalan 200 mg/m2 as Preparative Regimen for Autologous Transplantation in Multiple Myeloma
Reduced Intensity Conditioning (RIC) Regimen Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients (PTS) With Acute Lymphoblastic Leukemia (ALL)
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
BACKGROUND: This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge. CASE PRESENTATION: A 77-year-old woman with advanced epithelioid mesothelioma extensively pretreated with chemotherapy demonstrated a prolonged response of 45 months to 52 cycles of pembrolizumab. On rechallenge with pembrolizumab, further disease stability was achieved. Serial biopsies and analysis by immunohistochemistry and immunofluorescence demonstrated marked immune infiltration and documented the emergency of markers of immune exhaustion. Whole exome sequencing demonstrated a reduction in tumor mutational burden consistent with subclone elimination by immune checkpoint inhibitor (CPI) therapy. The relapse biopsy had missense mutation in BTN2A1. CONCLUSION: This case supports rechallenge of programme death receptor 1 inhibitor in cases of previous CPI sensitivity and gives molecular insights
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Objectives Despite advances in novel drug development for patients with advanced non-small cell lung cancer (NSCLC), there are still only a limited number of approved treatments. We therefore evaluated the clinical outcomes of patients with advanced NSCLC referred to a dedicated phase I clinical trials unit assessed baseline clinical factors associated with successful enrollment onto phase I trials.Material and methods We conducted a retrospective study involving patients with advanced NSCLC referred to the Drug Development Unit at the RMH between January 2005 and December 2013.Results 257 patients with advanced NSCLC were referred for consideration of phase I trials, of which only 89 (35%) patients successfully commenced phase I trials. The commonest reasons for not entering study included poor ECOG performance status and rapid disease progression. A multivariate analysis identified that ECOG performance status (0-1) and RMH prognostic score (0-1) were associated with successful enrollment onto phase I trials (p<0.001). Single agent therapies included novel agents against the phosphatidylinositol-3 kinase pathway, insulin growth factor-1 receptor and pan-HER family tyrosine kinases. These trial therapies were well tolerated and mainly associated with grade 1-2 adverse events, with a minority experiencing grade 3 toxicities. Nine (10%) patients, 4 with known EGFR or KRAS mutations, achieved RECIST partial responses. Median time to progression was 2.6 months and median overall survival was 8.1 months for patients enrolled.Conclusions Phase I trial therapies were generally well tolerated with potential antitumor benefit for patients with advanced NSCLC. Early referral to drug development units at time of disease progression should be considered to enhance the odds of patient participation in these studies
- …